Oncology Central

Predictive biomarkers to anti-EGF receptor inhibitors in the treatment of metastatic colorectal cancer


The prognosis of patients harboring metastatic colorectal cancer (CRC) remains poor despite therapeutic improvements obtained in recent years thanks to new biologic agents. A resistance mechanism limits the effectiveness of current cancer therapies to treat metastatic CRC patients. The identification of mechanisms of drug resistance may highlight new biomarkers useful to predict the clinical outcome or the likely responsiveness to pharmacological treatment of those metastatic CRC patients who cannot benefit from current therapeutic regimen.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.